Skip to main content

Summary

for people ages 18–85 (full criteria)
at San Francisco, California
study started
estimated completion:

Description

Summary

This is a prospective, Phase 2, single center, open-label study in adult patients with presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate PET/MR prior to surgery.

Official Title

68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults

Keywords

Glioma Citric Acid

Eligibility

You can join if…

Open to people ages 18–85

  • WHO grade 3 or 4 glioma planning to undergo surgery
  • Age >= 18 years
  • Karnofsky performance status of >= 60
  • Ability to understand a written informed consent document, and the willingness to sign it

Cohort A - 20 subjects

  • Positive for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy Cohort B - 20 subjects
  • Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

You CAN'T join if...

  • Contraindications to PET imaging (e.g. pregnant or breast-feeding woman)
  • Contraindications to MR imaging (e.g. pacemakers, metallic implants, etc.)

Location

  • University of California, San Francisco accepting new patients
    San Francisco, California, 94107, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03335280
Lead Scientist
Michael Evans
Study Type
Observational
Last Updated
November 2, 2017
I’m interested in this study!